PENTYLONE

Description

Pentylone (β-Keto-Methyl​benzo​dioxolyl​pentanamine, βk-Methyl-K, βk-MBDP, methyl​enedioxy​pentedrone, or 1‐(3,4‐methylenedioxyphenyl)‐2‐(methylamino) pentan‐1‐one) is a stimulant developed in the 1960s. n-ethyl pentylone,n-ethyl-pentylone effects, drug uses, street name,ethylone

 It is a substituted cathinone (a type of substituted phenethylamine). It has been identified in some samples of powders sold as “NRG-1”, along with varying blends of other cathinone derivatives including mephedrone, MDPBP, MDPV, and 4-MePPP.

It was also found in combination with 4-MePPP being sold as “NRG-3”. Reports indicate side effects include feelings of paranoia, agitation, and inability to sleep, with effects lasting for several days at high doses.

It was also found in combination with 4-MePPP being sold as “NRG-3”.

Reports indicate side effects include feelings of paranoia, agitation, and inability to sleep, with effects lasting for several days at high doses.

Pentylone (hydrochloride) is an analytical reference material categorized as a cathinone.

Pentylone has been detected in products sold as bath salts.5-DBFPV

Pentylone is regulated as a Schedule I compound in the United States. This product is intended for research and forensic applications.

It is a synthetic cathinone. Synthetic cathinones were first synthesized in the late 1920s, starting with methcathinone and mephedrone.

However, they did not find medical use due to their side effects. In the early 2000s, synthetic cathinones began to be sold in “head” shops and online as designer drugs, also known as research chemicals and “legal highs”.

Their quasi-legality and ability to substitute for traditional stimulants like cocaine or amphetamine made them popular in certain demographics. Due to a history of being falsely marketed as bath salt products, they are referred to in the media as “bath salts.”n-ethyl pentylone,n-ethyl-pentylone effects, drug uses, street name,ethylone

The synthesis of pentylone was first described in a patent filed by Boehringer Ingelheim in 1969.

It was described alongside the synthesis of other novel central nervous system stimulants including butylone, dibutylone, and ephylone. nm-2201

However, its pharmacological properties were not tested and it was never marketed.MPHP